top of page

Domain Therapeutics creates new company to stop Parkinson’s disease progression

France-based biopharmaceutical firm Domain Therapeutics has established a new company, Mavalon Therapeutics, dedicated to develop a drug candidate to stop the progression of Parkinson’s disease.

Life sciences-focused venture capital firm Medicxi Ventures has agreed to invest up to €9m in Mavalon.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page